ArticleFrontiers in oncology2026

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study.

Zhenghua Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.